Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer
US11547705B2 · kind B2 · utility
3Cited by
110References
32Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 3, 2016 |
| Grant date | Jan 10, 2023 |
| Priority date | — |
| Expiry date | Mar 3, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I):
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.